This HTML5 document contains 23 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n11	http://linked.opendata.cz/resource/domain/vavai/cep/soutez/
n5	http://linked.opendata.cz/resource/domain/vavai/cep/kategorie/
dcterms	http://purl.org/dc/terms/
n2	http://linked.opendata.cz/resource/domain/vavai/cep/projekt/MSM/
n7	http://linked.opendata.cz/resource/domain/vavai/cep/aktivita/
n4	http://linked.opendata.cz/ontology/domain/vavai/
n8	http://linked.opendata.cz/resource/domain/vavai/cep/obor/
n10	http://linked.opendata.cz/resource/domain/vavai/cep/druh-souteze/
n12	http://linked.opendata.cz/resource/domain/vavai/cep/faze/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n9	http://linked.opendata.cz/resource/domain/vavai/cep/typ/
n6	http://linked.opendata.cz/resource/domain/vavai/cep/poskytovatel/
xsdh	http://www.w3.org/2001/XMLSchema#

Statements

Subject Item

n2:VS96149

rdf:type

n4:Projekt

dcterms:description

Budou sledovány možnosti ovlivnění systémové a slizniční imunity po orální imunizaci. Bude testován účinek různých adjuvancií, nosičů a vektorů: Bacillus firmus jako adjuvans a nosič (ervent. vektor), mutanta Escherichia coli 083 K24 H31 hlyA- jako živý vektor, adenylát-cyklázový é mechanismy uplatňující se při patogeneze celiakie. Výsledky mohou být využitelné pro rozvoj nových vakcinačních strategií. Possibilities of modulation of mucosal and systemic immunity after oral immunization will be studied. The effect of various adjuvants, carriers and vectors on induction of protective immunity or oral tolerance will be tested. Bacillus firmus has strong immunomodulatory activities and will be used as adjuvant and antigen carrier. A mutant of E. coli O83 K24 H31 hlyA- with excellent intestine colonizing properties will be used as live vector for tetanic toxin. Effectiveness of adenylate-cyclase toxin (ACT) of Bordetella pertussis as a constituent of subunit vaccine against pertussis will be followed. Integration of various heterologous epitopes into ACT can influence their presentation to lymphocytes and character of immune response. Chimeric ACT with gliadin epitopes will be exploited in the study of antigen presentation and its significance for pathogeny of celiac disease. The results expected could be used

dcterms:title

Strategy of oral immunization: significance for systemic and mucosal immunity and use for prevention and therapy Strategie orální imunizace, její výzkum pro systémovou a slizniční imunitu a využití k preventivním a léčebným účelům

n4:dalsi-vedlejsi-obor

n8:FO

n4:druh-souteze

n10:

n4:faze

n12:20063898

n4:hlavni-obor

n8:EA

n4:vedlejsi-obor

n8:EE

n4:id-aktivity

n7:VS

n4:id-souteze

n11:

n4:kategorie

n5:0

n4:klicova-slova

mucosal immunity; peroral immunization; oral tolerance; mucosal adjuvants; antigen carriers; mucosal

n4:pocet-koordinujicich-prijemcu

0

n4:poskytovatel

n6:MSM

n4:statni-podpora

14269

n4:typProjektu

n9:P

n4:uznane-naklady

51532

n4:pocet-prijemcu

1

n4:pocet-spoluprijemcu

0

n4:pocet-vysledku

23

n4:pocet-vysledku-zverejnovanych

23